Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which insulin dosing method works best for cystic fibrosis diabetes?

NCT ID NCT04533646

Disease control Sponsor: Jagdeesh Ullal Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two common methods of dosing mealtime insulin in people with cystic fibrosis-related diabetes: counting carbohydrates versus using a fixed dose. Researchers used continuous glucose monitors to track blood sugar levels and see which method kept glucose in a healthy range. The goal was to find the best way to manage blood sugar without causing too many lows or highs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

13 people

The number who actually took part.

Started

Sep 2020

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>18 age of years * Diagnosis of cystic fibrosis related diabetes * Using basal bolus insulin * Cystic Fibrosis with Lung Transplantation Exclusion Criteria: * Use of continuous glucose monitors * Patient unable to check fingerstick blood sugars

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cystic fibrosis-related diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cystic fibrosis-related diabetes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cystic fibrosis-related diabetes

Contacts and locations

Locations

  • University of Pittsburgh Medical Center, Center for Diabetes and Endocrinology

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.